You can buy or sell AbbVie and other stocks, options, ETFs, and crypto commission-free!
ABBVIE INC., also called AbbVie, is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. Read More The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.
North Chicago, Illinois
52 Week High
52 Week Low
Biotech Analysis Central Pharma News: AbbVie's Trouble, Merck KGaA's Bad Streak, Puma's Positive Data
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
AbbVie, Inc. ABBV announced that the FDA has placed a partial clinical hold on all studies evaluating its leukemia drug, Venclexta (venetoclax) for the treatment of multiple myeloma. The decision was taken after, in the ongoing phase III BELLINI study, a higher proportion of deaths were observed in the Venclexta arm compared to the control arm of the study. Following the observation, it has been instructed that until the data is further analyzed, no new patients should be enrolled in any studies of Venclex...
What Investors Are Missing About AbbVie
It looks as if AbbVie's (NYSE:ABBV) glorious days are over. The stock is down almost 30% from its 52-week high and down more than a third from its all-time high set in January 2018. It is substantially underperforming the S&P 500 this year with a performance of -12% compared to the S&P's 13% total return gain. Source: Seeking Alpha - Momentum statistics Are the glory days really over? What has changed since January 2018 that could warrant such a big decline in the stock price? Is the market overreacting o...
Expected Apr 26, Pre-Market